Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia

Cytometry Part B - Clinical Cytometry

Volumn 74, Issue 4, 2008, Pages 221-226

  Ahmad, Ejaz ^a   Steinberg, Seth M ^b   Goldin, Lynn ^b   Hess, Christopher J ^b   Caporaso, Neil ^b   Kreitman, Robert J ^b   Wiestner, Adrian ^c   Wilson, Wyndham ^b   White, Therese ^b   Marti, Gerald ^d   Stetler Stevenson, Maryalice ^b  

^a Good Samaritan Hospital Dayton   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d Center for Biologics Evaluation and Research   (United States)

Author keywords

CD38; Familial chronic lymphocytic leukemia; Flow cytometry; Immunophenotype; Sporadic chronic lymphocytic leukemia; Survival

Indexed keywords

CD103 ANTIGEN; CD19 ANTIGEN; CD2 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ALPHA; MEMBRANE ANTIGEN; MICROSOMAL AMINOPEPTIDASE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FAMILIAL CHRONIC LYMPHOCYTIC LEUKEMIA; FAMILY HISTORY; FEMALE; FLOW CYTOMETRY; GENETIC SUSCEPTIBILITY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SPORADIC CHRONIC LYMPHOCYTIC LEUKEMIA;

AGED; ANTIGENS, CD13; ANTIGENS, CD2; ANTIGENS, CD38; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 47549100875     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20423     Document Type: Article

References (29)

1. Hernandez J, Land KJ, McKenna RW. Leukemias, myeloma and other lymphoreticular neoplasms. Cancer 1995;75(Suppl. 1):381-394.
2. Faguet G. Chronic lymphocytic leukemia: An updated review. J Clin Oncol 1994;12:1974-1990.
3. Ishibe N, Sgambati MT, Fontaine L, Goldin LR, Jain N, Weissman N, Marti GE, Caporso NE. Clinical characteristics of familial B-CLL in the National Cancer Institute Familial Registry. Leuk Lymphoma 2001;42:99-108.
4. Fraumeni JF, Jr, V.C., DeVita VT. Familial chronic lymphocytic leukemia. Ann Intern Med 1969;71:279-284.
5. Sakai A, Marti GE, Caporaso N, Pittaluga S, Touchman JW, Fend F, Raffeld M. Analysis of expressed immunoglobulin heavy chain genes in familial B-CLL. Blood 2000;95:1413-1419.
6. Wiernik PH, Ashwin M, Hu XP, Paietta E, Brown K. Anticipation in familial chronic lymphocytic leukaemia. Br J Haematol 2001;113: 407-414.
7. Caporaso NE, WJ, Bertin P, Amos C, Papadopoulos N, Muller J, Whang-Peng J, Tucker MA, Fleisher TA, Marti GE. A 20 year clinical and laboratory study of familial B-chronic lymphocytic leukemia in a single kindred. Leuk Lymphoma 1991;3:331-342.
8. Goldin LR, Sgambati M, Marti GE, Fontaine L, Ishibe N, Caporaso N. Anticipation in familial chronic lymphocytic leukemia. Am J Hum Genet 1999;65:265-269.
9. Mauro FR, Giammartini E, Gentile M, Sperduti I, Valle V, Pizzuti A, Guarini A, Giannarelli D, Foà R. Clinical features and outcome of familial chronic lymphocytic leukemia. Haematologica 2006;91: 1117-1120.
10. Ishibe N, Prieto D, Hosack DA, Lempicki RA, Goldin LR, Raffeld M, Marti GE, Caporaso NE. Telomere length and heavy-chain mutation status in familial chronic lymphocytic leukemia. Leuk Res 2002;26: 791-794.
11. Marti G, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N, Aurran Schleinitz T, Caporaso N. On behalf of the international familial CLL consortium, diagnostic criteria for monoclonal B-cell lymphocytosis (MBL). Br J Haematol 2005;130:325-332.
12. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
13. Ahmad E, Kingma DW, Jaffe ES, Schrager JA, Janik J, Wilson W, Stetler-Stevenson M. Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow. Clin Cytometry B 2005;67B:6-12.
14. Faguet GB, A.J, Marti GE. Clone emergence and evolution in chronic lymphocytic leukemia: Characterization of clinical laboratory, and immunophenotypic profiles of 25 patients. Leuk Lymphoma I992;6: 345-356.
15. Daugherty SE, Pfeiffer RM, Mellemkjaer L, Hemminki K, Goldin LR. No evidence for anticipation in lymphoproliferative tumors in population-based samples. Cancer Epidemiol Biomarkers Prev 2005;14: 1245-1250.
16. Ng D, Toure O, Weil M, Arthur DC, Abbasi F, Fontaine L, Marti GE, Fraumeni JF, Goldin LR, Caporaso N, Toro JR. Identification of a novel chromosome region 13q21.33-q22.2 for susceptibility genes in familial chronic lymphocytic leukemia. Blood 2006;109:916-925.
17. Aoun P (Aoun, P., Zhou G (Zhou, Guimei), Chan WC (Chan, Wing C.), Page C (Page, Cynthia), Neth K (Neth, Kellie), Pickering D (Pickering, Diane), Sanger W (Sanger, Warren), Quinn-Laquer B (Quinn-Laquer, Brigid), Watson P (Watson, Patrice), Lynch JF (Lynch, Jane F.), Lynch HT (Lynch,Henry T.), Weisenburger DD (Weisenburger, Dennis D.), Familial B-cell chronic lymphocytic leukemia - Analysis of cytogenetic abnormalities, immunophenotypic profiles, and immunoglobulin heavy chain gene usage. Am J Clin Pathol 2007;127:31-38.
18. Ishibe N, Goldin LR, Caporaso NE. ATM mutations and protein expression are not associated with familial B-CLL cases. Leuk Res 2003;27:973-975.
19. Matutes E, Owusu-Ankomah K, Morula R, Garcia Marco J, Houlihan A, Que TH, Catovsky D. The immunological profile of B-Cell disorders and proposal of a scoring system for the diagnosis of CLL. leukemia 1994;8:1640-1645.
20. Stetler-Stevenson M, Schrager JA. In: McCoy JP, Carey JL, Keren DF, editors. Flow Cytometry in Clinical Diagnosis. 4th ed. Chicago: ASCP Press; 2006.
21. Kingma DW, Imus P, Xie XY, Jasper G, Sorbara L, Stewart C, Stetler-Stevenson M. CD2 is expressed by a sub-population of normal B cells and is frequently present in mature B cell neoplasms. Clin Cytom 2002;50:243-248.
22. Hjalmar V, Hast R, Kimby E. Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course. Eur J Haematol 2002;68:127-134.
23. Chang CL, CZ, Cleveland RP. Relative importance of CD38 expression over myeloid-associated markers expression in predicting the clinical course of B-CLL patients. Leuk lymphoma 2003;44:977-982.
24. Damle R, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.
25. Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno AM, Capelli G, Tamburini A, Suppo G, Battaglia A, Del Principe MI, Del Moro B, Masi M, Amadori S. Clinical signigifcance of CD38 expression in chronic lymphocytic leukemia. Blood 2001;98:2633-2639.
26. Hamblin TJ, Orchard JA, Ibotson RE, Davis Z, Thomas PW, Stevenson FK, Oscier DG. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-1029.
27. Hsi E, Kopecky KJ, Appelbaum FR, Boldt D, Frey T, Loftus M, Hussein MA. Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. Blood 2003;120:1017-1025.
28. Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I, Lerner S, Kantarjian HM, Albitar M. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001;98:181-186.
29. Ishibe N, Albitar M, Dilani IB, Golden LR, Marti GE, Caporaso NE. CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not. Blood 2002; 100:1100-1101.